[Correspondence] Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer – Authors' reply

We greatly appreciate the constructive comments from Rafael Rosell, Fang Wu, Tao Hou, and their colleagues on the ADJUVANT trial.1 We agree with Wu, Hou, and their colleagues that overall survival should be a crucial indication for changing the clinical practice. However, before the introduction of EGFR tyrosine-kinase inhibitors (TKIs), chemotherapy only provided 8 –10 months overall survival benefit for patients with advanced non-small-cell lung cancer (NSCLC).2 Use of TKIs as a first-line or later therapy, has been shown to increase overall survival to at least 22 months in patients with EGFR-mutant NSCLC.

Source: The Lancet Oncology - March 1, 2018 Category: Cancer & Oncology Authors: Yi-Long Wu, Wen-Zhao Zhong Tags: Correspondence Source Type: research